METHOD FOR PREDICTING THE RISK OF DEVELOPING ACUTE LEFT VENTRICULAR FAILURE IN THE FORM OF CARDIOGENIC SHOCK OR PULMONARY EDEMA IN PATIENTS WITH ACUTE CORONARY SYNDROME IN COMBINATION WITH THE SYNDROME OF UNDIFFERENTIATED CONNECTIVE TISSUE DYSPLASIA Russian patent published in 2022 - IPC G01N33/68 G01N33/543 A61B5/145 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to therapy and cardiology, and can be used to predict the risk of developing acute left ventricular failure in the form of cardiogenic shock or pulmonary edema in patients with acute coronary syndrome in combination with undifferentiated connective tissue dysplasia syndrome. In blood serum, the level of homocysteine and magnesium is determined by enzyme immunoassay and the probability of developing cardiogenic shock or pulmonary edema over the next 7 days is calculated using the formula: . At p<0.5, a low risk of developing cardiogenic shock or pulmonary edema is predicted. At p≥0.5, a high risk of developing cardiogenic shock or pulmonary edema is predicted.

EFFECT: method provides effective prediction of the risk of developing acute left ventricular failure in the form of cardiogenic shock or pulmonary edema in patients with acute coronary syndrome in combination with undifferentiated connective tissue dysplasia syndrome by determining the level of homocysteine and magnesium in blood serum.

1 cl, 3 ex